Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
DCF Valuation
Base-case fair value
$3180.42
Intrinsic $4240.56 · 25% MOS
Current price: $2.27
Base-case summary
Our base-case DCF for TherapeuticsMD, Inc. (TXMD) projects 10 years of free cash flow growth at 2.0% for years 1–5 and 1.0% for years 6–10, anchored to a default 8% growth assumption, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $3M in trailing free cash flow, this produces an intrinsic value of $4240.56 per share. A 25% safety margin gives a fair value of $3180.42, suggesting the stock is currently 140007% undervalued against the $2.27 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$3M
Cash & equivalents
$8M
Total debt
$6M
Shares outstanding
11640